The results of the in vitro studies revealed that the combination of statin and TKI exerted additive cytotoxic effects against human CML cells and mouse BaF3 cells (including those harboring ABL1 kinase domain mutations, such as the T315I mutation). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.